Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | REC-617 |
| Trade Name | |
| Synonyms | REC 617REC617GTAEXS 617|GTAEXS-617|GTAEXS617 |
| Drug Descriptions |
REC-617 (GTAEXS617) inhibits CDK7, potentially resulting in cell cycle arrest, increased apoptosis, and reduced proliferation of tumor cells, and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 3930, (Cancer Res (2025) 85 (8_Supplement_1): 366)). |
| DrugClasses | CDK7 Inhibitor 16 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Paclitaxel + REC-617 | Bevacizumab Paclitaxel REC-617 | 0 | 1 |
| Capecitabine + REC-617 | Capecitabine REC-617 | 0 | 1 |
| Fulvestrant + REC-617 | Fulvestrant REC-617 | 0 | 1 |
| Pegylated liposomal doxorubicin + REC-617 | Pegylated liposomal doxorubicin REC-617 | 0 | 1 |
| REC-617 | REC-617 | 1 | 2 |